Suppr超能文献

间位-[¹³¹I]-和间位-[¹²⁵I]碘苄胍对不同大小神经母细胞瘤多细胞肿瘤球体的治疗作用。

Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.

作者信息

Weber W, Weber J, Senekowitsch-Schmidtke R

机构信息

Department of Nuclear Medicine, Technische Universität München, Munich, Germany.

出版信息

Cancer Res. 1996 Dec 1;56(23):5428-34.

PMID:8968097
Abstract

m-[l25I]iodobenzylguanidine (m-[125I]MIBG) has been suggested as an alternative to m-[131I]MIBG for the treatment of metastatic neuroblastoma to achieve a higher radiation dose in micrometastases. To compare these two radiopharmaceuticals, a mathematical model was developed in the present study that allows for the calculation of radiation dose rates within small spherical tumors for different distributions of 131I and 125I. Furthermore, the relationship between tumor size and the therapeutic effects of m-[131I]- and m-[125I]MIBG was studied in vitro using multicellular tumor spheroids of the neuroblastoma cell line SK-N-SH. According to the calculations, higher mean dose rates can be achieved by m-[125I]MIBG than by m-[131I]MIBG up to a tumor diameter of 100 microm when both substances are homogeneously distributed within the tumor. In larger tumors, however, mean dose rates achieved by 131I are up to 8-fold higher. Evaluation of various activity distributions demonstrated that even in tumors of less than 100 microm in diameter, marked heterogeneities of the dose rate can occur when m-[125I]MIBG is not distributed homogeneously. By treatment with m-[131I]MIBG, the growth of tumor spheroids ranging from 100 to 250 microm in diameter was inhibited more effectively in the larger than in the smaller spheroids. The growth inhibition of spheroids treated with m-[125I]MIBG was independent of the spheroid size. In consistency with the calculations, the therapeutic effect of m-[125I]- and m-[131I]MIBG was equal in spheroids with diameters of about 100 microm. In larger spheroids, m-[131I]MIBG induced a more pronounced delay in spheroid growth than m-[125I]MIBG. According to these calculations and in vitro data, m-[125I]MIBG as a single agent does not seem to be a promising alternative to m-[131I]MIBG for treatment of metastatic neuroblastoma. However, the combined use of m-[131I]- and m-[125I]MIBG may be more effective than treatment with m-[131I]MIBG alone.

摘要

间位-[¹²⁵I]碘苄胍(m-[¹²⁵I]MIBG)已被提议作为间位-[¹³¹I]MIBG的替代物用于治疗转移性神经母细胞瘤,以便在微转移灶中实现更高的辐射剂量。为了比较这两种放射性药物,本研究建立了一个数学模型,该模型可以计算¹³¹I和¹²⁵I不同分布情况下小球形肿瘤内的辐射剂量率。此外,使用神经母细胞瘤细胞系SK-N-SH的多细胞肿瘤球体在体外研究了肿瘤大小与间位-[¹³¹I]-和间位-[¹²⁵I]MIBG治疗效果之间的关系。根据计算结果,当两种物质在肿瘤内均匀分布时,在肿瘤直径达100微米时,间位-[¹²⁵I]MIBG可实现比间位-[¹³¹I]MIBG更高的平均剂量率。然而,在更大的肿瘤中,¹³¹I实现的平均剂量率高出多达8倍。对各种活度分布的评估表明,即使在直径小于100微米的肿瘤中,当间位-[¹²⁵I]MIBG分布不均匀时,剂量率也会出现明显的异质性。通过间位-[¹³¹I]MIBG治疗,直径在100至250微米之间的肿瘤球体,较大的球体比较小的球体生长受到更有效的抑制。间位-[¹²⁵I]MIBG处理的球体生长抑制与球体大小无关。与计算结果一致,在直径约100微米的球体中,间位-[¹²⁵I]-和间位-[¹³¹I]MIBG的治疗效果相同。在更大的球体中,间位-[¹³¹I]MIBG比间位-[¹²⁵I]MIBG诱导的球体生长延迟更明显。根据这些计算结果和体外数据,间位-[¹²⁵I]MIBG作为单一药物似乎不是治疗转移性神经母细胞瘤的间位-[¹³¹I]MIBG的有前景的替代物。然而,间位-[¹³¹I]-和间位-[¹²⁵I]MIBG联合使用可能比单独使用间位-[¹³¹I]MIBG更有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验